Marksans Pharma Limited announced today that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization for Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution from the UK’s Medicines & Healthcare Products Regulatory Agency (MHRA).
The product, used primarily for treating overactive bladder and urinary incontinence, expands Marksans’ offering in the urology therapeutic segment and strengthens its European portfolio.
The company, headquartered in Mumbai, manufactures and markets generic pharmaceutical formulations globally, with facilities in India, the US, and the UK—approved by regulatory bodies including the USFDA, UKMHRA, and Australia’s TGA.
“This approval further reinforces our commitment to expanding our presence in regulated markets through high-quality generic products,” the company said in a press release.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
